Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18341468 | 0.89 | — | — | |
| SCHEMBL16050379 | 0.72 | — | — | |
| SCHEMBL2010151 | 0.69 | ALDH1A1 (0.34) | CYP2C19ALDH1A1LMNAPOLB | |
| SCHEMBL320082 | 0.69 | CYP4F2 (0.35) | CYP2C19MEN1KMT2AALDH1A1LMNA | |
| SCHEMBL5860682 | 0.69 | CD274 (0.33) | CYP2C19MEN1KMT2AALDH1A1LMNA | |
| SCHEMBL12985009 | 0.69 | — | — | |
| SCHEMBL29131768 | 0.68 | ALDH1A1 (0.33) | CYP2C19MEN1KMT2AALDH1A1LMNA | |
| SCHEMBL19117998 | 0.67 | — | — | |
| SCHEMBL30203333 | 0.67 | ALDH1A1 (0.33) | CYP2C19MEN1KMT2AALDH1A1LMNA | |
| SCHEMBL25187231 | 0.66 | CD274 (0.40) | CYP2C19MEN1KMT2AALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114269753-B | Nitrogen-containing bicyclic compound, pharmaceutical composition containing same, preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2024-03-05 | — | — | CN | claimed |
| CN-114269753-A | Nitrogen-containing fused ring compound, pharmaceutical composition containing nitrogen-containing fused ring compound, preparation method and application of nitrogen-containing fused ring compound | 四川科伦博泰生物医药股份有限公司 | 2022-04-01 | — | — | CN | claimed |
| EP-2847174-B1 | PYRIMIDINONE CARBOXAMIDES AS INHIBITORS OF ENDOTHELIAL LIPASE | BRISTOL MYERS SQUIBB CO (US) | 2017-05-17 | — | — | EP | claimed |
| EP-2844643-B1 | PYRIMIDINEDIONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE | BRISTOL MYERS SQUIBB CO (US) | 2016-11-30 | — | — | EP | claimed |
| US-9394260-B2 | Pyrimidinone carboxamide inhibitors of endothelial lipase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-07-19 | — | — | US | claimed |
| US-20150361052-A1 | PYRIMIDINONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE | BRISTOL-MYERS SQUIBB COMPANY | 2015-12-17 | — | — | US | claimed |
| US-9199946-B2 | Pyrimidinone carboxamide inhibitors of endothelial lipase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-12-01 | — | — | US | claimed |
| EP-2847174-A1 | PYRIMIDINONE CARBOXAMIDES AS INHIBITORS OF ENDOTHELIAL LIPASE | Bristol-Myers Squibb Company (US) | 2015-03-18 | — | — | EP | claimed |
| EP-2844643-A1 | PYRIMIDINEDIONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE | Bristol-Myers Squibb Company (US) | 2015-03-11 | — | — | EP | claimed |
| US-20150065505-A1 | PYRIMIDINONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-03-05 | — | — | US | claimed |
| WO-2013151923-A1 | PYRIMIDINONE CARBOXAMIDES AS INHIBITORS OF ENDOTHELIAL LIPASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-10-10 | — | — | WO | claimed |
| WO-2013151877-A1 | PYRIMIDINEDIONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-10-10 | — | — | WO | claimed |
| CN-114269753-B | Nitrogen-containing bicyclic compound, pharmaceutical composition containing same, preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2024-03-05 | — | — | CN | disclosed |
| CN-114269753-A | Nitrogen-containing fused ring compound, pharmaceutical composition containing nitrogen-containing fused ring compound, preparation method and application of nitrogen-containing fused ring compound | 四川科伦博泰生物医药股份有限公司 | 2022-04-01 | — | — | CN | disclosed |
| CN-109328059-B | Selective inhibitors of clinically important mutants of EGFR tyrosine kinase | CS制药技术有限公司 | 2021-08-17 | — | — | CN | disclosed |
| WO-2021057256-A1 | HETEROCYCLIC NITROGEN COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, PREPARATION METHOD THEREFOR AND USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2021-04-01 | — | — | WO | disclosed |
| US-20090306055-A1 | PHENYLAZOLE COMPOUNDS, PRODUCTION PROCESS AND ANTIOXIDANTS | NIPPON SODA CO., LTD. (JP) | 2009-12-10 | — | — | US | disclosed |
| US-7553837-B2 | Phenylazole compounds production process and antioxidants | NIPPON SODA CO., LTD. (JP) | 2009-06-30 | — | — | US | disclosed |
| US-20060247228-A1 | Phenylazole compounds production process and antioxidants | NIPPON SODA CO., LTD. (JP) | 2006-11-02 | — | — | US | disclosed |
| EP-1650206-A1 | PHENYLAZOLE COMPOUNDS, PRODUCTION PROCESS, AND ANTIOXIDANTS | NIPPON SODA CO., LTD. (JP) | 2006-04-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150361052-A1 | PYRIMIDINONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE | LIPG, LPL, PNLIP | CYP2C19 616/4885MEN1 3703/4885KMT2A 1468/4885 |
| US-20090306055-A1 | PHENYLAZOLE COMPOUNDS, PRODUCTION PROCESS AND ANTIOXIDANTS | NOX1, CBR1, AOX1 | CYP2C19 384/4885MEN1 4566/4885KMT2A 4517/4885 |
| US-20060247228-A1 | Phenylazole compounds production process and antioxidants | CBR1, CBR3, NOX3 | CYP2C19 315/4885MEN1 4516/4885KMT2A 4566/4885 |
| US-20150065505-A1 | PYRIMIDINONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE | LIPG, LPL, PNLIP | CYP2C19 606/4885MEN1 4150/4885KMT2A 1409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.